<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211221053471N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-23</date_registration>
      <primary_sponsor>Babol University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of gel containing chitosan in grade II furcation involvement defects</public_title>
      <acronym></acronym>
      <scientific_title>Clinical and radiographic investigation of the effect of gel containing chitosan in grade II furcation involvement defects</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72817</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The randomization process is done based on the Kitset.ir site and the random numbers option, and in each of the samples, a gel containing chitosan and a gel without chitosan are randomly placed.According to the mentioned site, group A includes numbers
29,7,6,8,25,22,16,43,27,31,2,28,44,33,23,9,10,4,12,35,11,32
and group B including numbers
17,37,38,42,26,20,14,24,21,3,13,36,34,39,40,19,15,30,41,5,18,1
is, Blinding description: Me and the professor of surgery, as a researcher and performing surgeries, will not have any information about the contents of the gels, nor will the data analyst and the participants have any information. What does the gel contain.</study_design>
      <phase>N/A</phase>
      <hc_freetext>grade II furcation involvement defects.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A gel containing chitosan is randomly placed in each of the samples. Intervention 2: Control group: Chitosan-free gel is randomly placed in each sample.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data and outcome changes are available

When:
After completing the study

To whom:
All researchers related to the subject

Conditions:
According to the relevant protocol

Where to obtain:
Researcher in charge via e-mail

How to obtain:
E-mail and then check the reason for the need for data

Comments:
Confidentiality of patients' personal information is maintained.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parastoo Madieh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Second alley on the leftوHar St. 21, Shahabnia intersection,Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4718773564</zip>
        <telephone>+98 991 151 0075</telephone>
        <email>parastoomadieh@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Parastoo Madieh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Second alley on the leftوHar St. 21, Shahabnia intersection,Babol</address>
        <city>Babol</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4718773564</zip>
        <telephone>+98 51 3840 5446</telephone>
        <email>parastoomadieh@gmail.com</email>
        <affiliation>Babol University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients with moderate to severe chronic periodontitis with grade II furcation involvement on the lingual or buccal side of the first or second molar of the lower jaw and need treatment.
.Index plaque before surgery should be less than 20%
The horizontal probe depth (Horizontal Probe Depth, HPD) in the involved areas is greater than or equal to 3.</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having a systemic disease
Need for prophylactic antibiotics to prevent bacterial endocarditis
Use of medications that interfere with periodontal healing
smoking
Presence of contraindications for periodontal surgery
Teeth with anatomical complications such as CEP, bifurcation ridge, accessory canal and concavity
More tooth mobility than class II
Presence of decay and repair in the furcation area
Presence of evidence of periapical pathology in the clinical or radiographic appearance of the tooth in question
The possibility of the patient's lack of acceptable cooperation after the initial periodontal treatment
Having a history of coagulation problems</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>XVIII</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A gel containing chitosan is randomly placed in each of the samples.</i_keyword>
      <i_keyword>Control group: Chitosan-free gel is randomly placed in each sample.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>(Vertical probing depth) VPD: means the distance between the margin of the gum to the point where the gum epithelium adheres to the surface of the tooth, which is measured by the probe. To measure the depth of the pocket, the calibrated periodontal probe is inserted from the facial, lingual, mesial and distal surfaces of the tooth so that the tip of the probe is parallel to the longitudinal axis of the tooth, enters the gingival sulcus and the depth of the pocket is measured. The numbers obtained in the file related to Each patient is registered. Timepoint: At the beginning of the study (before surgery) and 6 months after surgery. Method of measurement: Clinical parameters are measured using a periodontal probe by the examiner. and the parameters are recorded. The initial radiograph (before surgery) will be taken using Rinn Xcp.Dentsply (Sirona.USA-Newyork) protective film and PSP digital sensor (Soredex.Helsinki-Finland) size 2 and for record keeping The occlusion of the patient is performed using Duralay (Reliance.Illiniois-America) molding material from the bite block area of the film holding the patient's occlusion. The images are processed and then saved using PCT (Soredex.Helsinki-Finland) and DFW2.5 software (Soredex.Helsinki-Finland) and recorded 6 months later using a byte block and PSP digital sensor (Soredex. Helsinki-Finland) size 2 and the same exposure parameters, a second radiograph is performed. Then, digital subtraction of the images before and after the treatment is done by Photoshop CS6 software (Adobe systems.California-America). In the cases where the difference in density is observed as radiolucency as analysis, the cases that were observed as radiopacity as bone formation in the area and in cases where the change that is not observed in terms of density are considered unchanged.</prim_outcome>
      <prim_outcome>(Vertical clinical attachment level) VCAL: First, the CEJ of the desired tooth is determined by a probe, the distance from the edge of the margin to this area is recorded by the probe, the difference of this number is the depth of probing VCAL. Timepoint: At the beginning of the study (before surgery) and 6 months after surgery. Method of measurement: Clinical parameters are measured using a periodontal probe by the examiner. and the parameters are recorded. The initial radiograph (before surgery) will be taken using Rinn Xcp.Dentsply (Sirona.USA-Newyork) protective film and PSP digital sensor (Soredex.Helsinki-Finland) size 2 and for record keeping The occlusion of the patient is performed using Duralay (Reliance.Illiniois-America) molding material from the bite block area of the film holding the patient's occlusion. The images are processed and then saved using PCT (Soredex.Helsinki-Finland) and DFW2.5 software (Soredex.Helsinki-Finland) and recorded 6 months later using a byte block and PSP digital sensor (Soredex. Helsinki-Finland) size 2 and the same exposure parameters, a second radiograph is performed. Then, digital subtraction of the images before and after the treatment is done by Photoshop CS6 software (Adobe systems.California-America). In the cases where the difference in density is observed as radiolucency as analysis, the cases that were observed as radiopacity as bone formation in the area and in cases where the change that is not observed in terms of density are considered unchanged.</prim_outcome>
      <prim_outcome>(Horizontal probing depth) HPD: is the horizontal entry of the probe into the furcation. Timepoint: At the beginning of the study (before surgery) and 6 months after surgery. Method of measurement: Clinical parameters are measured using a periodontal probe by the examiner. and the parameters are recorded. The initial radiograph (before surgery) will be taken using Rinn Xcp.Dentsply (Sirona.USA-Newyork) protective film and PSP digital sensor (Soredex.Helsinki-Finland) size 2 and for record keeping The occlusion of the patient is performed using Duralay (Reliance.Illiniois-America) molding material from the bite block area of the film holding the patient's occlusion. The images are processed and then saved using PCT (Soredex.Helsinki-Finland) and DFW2.5 software (Soredex.Helsinki-Finland) and recorded 6 months later using a byte block and PSP digital sensor (Soredex. Helsinki-Finland) size 2 and the same exposure parameters, a second radiograph is performed. Then, digital subtraction of the images before and after the treatment is done by Photoshop CS6 software (Adobe systems.California-America). In the cases where the difference in density is observed as radiolucency as analysis, the cases that were observed as radiopacity as bone formation in the area and in cases where the change that is not observed in terms of density are considered unchanged.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Gingival recession: if the gingival margin is below the CEJ, we consider its existence as positive, and if the gingival margin is above the CEJ, this parameter is recorded as absent. Timepoint: At the beginning of the study (before surgery) and 6 months after surgery. Method of measurement: Clinical parameters are measured using a periodontal probe by the examiner. and the parameters are recorded. The initial radiograph (before surgery) will be taken using Rinn Xcp.Dentsply (Sirona.USA-Newyork) protective film and PSP digital sensor (Soredex.Helsinki-Finland) size 2 and for record keeping The occlusion of the patient is performed using Duralay (Reliance.Illiniois-America) molding material from the bite block area of the film holding the patient's occlusion. The images are processed and then saved using PCT (Soredex.Helsinki-Finland) and DFW2.5 software (Soredex.Helsinki-Finland) and recorded 6 months later using a byte block and PSP digital sensor (Soredex. Helsinki-Finland) size 2 and the same exposure parameters, a second radiograph is performed. Then, digital subtraction of the images before and after the treatment is done by Photoshop CS6 software (Adobe systems.California-America). In the cases where the difference in density is observed as radiolucency as analysis, the cases that were observed as radiopacity as bone formation in the area and in cases where the change that is not observed in terms of density are considered unchanged.</sec_outcome>
      <sec_outcome>Gingival Index: based on the percentage of tooth surfaces. which has inflammation, determines the severity and existence of gingivitis. and Subtraction Radiography based on the formation or lack of bone formation in the parallel periapical. Timepoint: At the beginning of the study (before surgery) and 6 months after surgery. Method of measurement: Clinical parameters are measured using a periodontal probe by the examiner. and the parameters are recorded. The initial radiograph (before surgery) will be taken using Rinn Xcp.Dentsply (Sirona.USA-Newyork) protective film and PSP digital sensor (Soredex.Helsinki-Finland) size 2 and for record keeping The occlusion of the patient is performed using Duralay (Reliance.Illiniois-America) molding material from the bite block area of the film holding the patient's occlusion. The images are processed and then saved using PCT (Soredex.Helsinki-Finland) and DFW2.5 software (Soredex.Helsinki-Finland) and recorded 6 months later using a byte block and PSP digital sensor (Soredex. Helsinki-Finland) size 2 and the same exposure parameters, a second radiograph is performed. Then, digital subtraction of the images before and after the treatment is done by Photoshop CS6 software (Adobe systems.California-America). In the cases where the difference in density is observed as radiolucency as analysis, the cases that were observed as radiopacity as bone formation in the area and in cases where the change that is not observed in terms of density are considered unchanged.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Babol University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-09-27</approval_date>
        <contact_name>Ethics Committee of Babol University of Medical Sciences</contact_name>
        <contact_address>Second alley on the leftوHar St. 21, Shahabnia intersection,Babol Babol Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
